BioPharmX Corporation Granted Pre-IND Meeting With
Post# of 223
Posted On: 01/12/2015 12:17:38 PM
BioPharmX Corporation Granted Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution
MENLO PARK, Calif., Jan. 12, 2015 /PRNewswire/ -- BioPharmX Corporation (BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has been granted a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration to discuss the company's topical antibiotic acne compound currently under development. The meeting, currently scheduled for March 2015, is expected to focus on the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials.
"We're very pleased with the FDA's decision to grant a meeting with BioPharmX and with our continued progress toward advancing the development of our topical antibiotic acne compound," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX.
MENLO PARK, Calif., Jan. 12, 2015 /PRNewswire/ -- BioPharmX Corporation (BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has been granted a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration to discuss the company's topical antibiotic acne compound currently under development. The meeting, currently scheduled for March 2015, is expected to focus on the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials.
"We're very pleased with the FDA's decision to grant a meeting with BioPharmX and with our continued progress toward advancing the development of our topical antibiotic acne compound," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX.
(0)
(0)